Andreas A Argyriou
Overview
Explore the profile of Andreas A Argyriou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
2444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Dermitzakis E, Kouroudi A, Argyriou A, Spingos K, Bilias K, Vikelis M
Medicina (Kaunas)
. 2023 Jan;
59(1).
PMID: 36676655
The Greek Society of Migraine and Headache Patients conducted, in 2020, its second online survey, titled "Migraine in Greece-2020", after publication of the first similar online survey conducted in 2018....
22.
Alberti P, Salvalaggio A, Argyriou A, Bruna J, Visentin A, Cavaletti G, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551575
Various neurological complications, affecting both the central and peripheral nervous system, can frequently be experienced by cancer survivors after exposure to conventional chemotherapy, but also to modern immunotherapy. In this...
23.
Argyriou A, Dermitzakis E, Xiromerisiou G, Vikelis M
Toxins (Basel)
. 2022 Dec;
14(12).
PMID: 36548744
We sought to assess the effectiveness of combining dual therapy with onabotulinumtoxinA (BTX) add-on to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (anti-CGRP MAbs) in treatment-refractory patients with chronic migraine (CM)....
24.
Dermitzakis E, Kouroudi A, Argyriou A, Spingos K, Bilias K, Vikelis M
BMC Neurol
. 2022 Nov;
22(1):440.
PMID: 36411425
The Greek Society of Migraine and Headache Patients (GSMHP), maintaining a strong commitment to research and information, conducted its second web-based online survey named "Migraine in Greece-2020", following its first...
25.
Mantovani E, Demrozi F, Hertz D, Turetta C, Ferro O, Argyriou A, et al.
J Peripher Nerv Syst
. 2022 Oct;
27(4):238-258.
PMID: 36224713
Chemotherapy-induced peripheral neurotoxicity (CIPN) diagnosis is largely based on patient reported outcomes. Wearables, sensors, and smart devices may potentially provide early detection and monitoring of CIPN. We systematically reviewed data...
26.
Dermitzakis E, Vikelis M, Vlachos G, Argyriou A
Toxins (Basel)
. 2022 Jul;
14(7).
PMID: 35878172
Background: We aimed to prospectively assess the role of needle length in improving the tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis, with a specific focus on neck...
27.
Argyriou A, Mantovani E, Mitsikostas D, Vikelis M, Tamburin S
Expert Rev Neurother
. 2022 Jun;
22(6):469-488.
PMID: 35707907
Introduction: Gepants are small molecules targeting the calcitonin gene-related peptide (CGRP) that have been recently introduced and are under additional clinical development as preventive and abortive treatment options for migraine....
28.
Dermitzakis E, Vikelis M, Vlachos G, Argyriou A
Toxins (Basel)
. 2022 May;
14(5).
PMID: 35622543
We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods:...
29.
Karteri S, Bruna J, Argyriou A, Mariotto S, Velasco R, Alemany M, et al.
J Peripher Nerv Syst
. 2022 Apr;
27(2):166-174.
PMID: 35384143
Our aim was to assess the significance of measuring serum neurofilament light chain (sNfL) levels as a biomarker of paclitaxel-induced peripheral neurotoxicity (PIPN). We longitudinally measured sNfL in breast cancer...
30.
Argyriou A, Dermitzakis E, Vlachos G, Vikelis M
Acta Neurol Scand
. 2022 Feb;
145(6):676-683.
PMID: 35170031
Background: OnabotulinumtoxinA (BoNTA) demonstrated a positive benefit-risk in chronic migraine (CM) patients in PREEMPT I and II phase III trials and many subsequent real-world studies. We herein aimed at evaluating...